Haruki Uojima
Kitasato University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Haruki Uojima.
Hepatology Research | 2017
Haruki Uojima; Takeshi Kinbara; Hisashi Hidaka; Ji Hyun Sung; Masachika Ichida; Shinnosuke Tokoro; Sakue Masuda; Satoshi Takizawa; Akiko Sasaki; Kazuya Koizumi; Hideto Egashira; Makoto Kako
To assess the correlation between response to tolvaptan and treatment‐related factors in liver cirrhosis patients.
Journal of Gastroenterology | 2018
Hidenori Toyoda; Masanori Atsukawa; Koichi Takaguchi; Tomonori Senoh; Kojiro Michitaka; Atsushi Hiraoka; Shinichi Fujioka; Chisa Kondo; Tomomi Okubo; Haruki Uojima; Toshifumi Tada; Hirohito Yoneyama; Tsunamasa Watanabe; Toru Asano; Hideyuki Tamai; Hiroshi Abe; Keizo Kato; Kunihiko Tsuji; Chikara Ogawa; Noritomo Shimada; Etsuko Iio; Akihiro Deguchi; Ei Itobayashi; Shigeru Mikami; Akio Moriya; Hironao Okubo; Joji Tani; Akihito Tsubota; Yasuhito Tanaka; Tsutomu Masaki
BackgroundThe real-world virological efficacy and safety of an interferon (IFN)-free direct-acting antiviral (DAA) therapy with elbasvir (EBR) and grazoprevir (GZR) were evaluated in Japanese patients chronically infected with hepatitis C virus (HCV) genotype 1.MethodsThe rate of sustained virologic response (SVR) and safety were analyzed in patients who started the EBR/GZR regimen between November 2016 and July 2017. SVR rates were compared based on patient baseline characteristics.ResultsOverall, 371 of 381 patients (97.4%) achieved SVR. Multivariate analysis identified a history of failure to IFN-free DAA therapy and the presence of double resistance-associated substitutions (RASs) in HCV non-structural protein 5A (NS5A) as factors significantly associated with failure to EBR/GZR treatment. The SVR rates of patients with a history of IFN-free DAA therapy and those with double RASs were 55.6 and 63.6%, respectively. In all other subpopulations, the SVR rates were more than 90%. There were no severe adverse events associated with the treatment.ConclusionsThe EBR/GZR regimen yielded high virological efficacy with acceptable safety. Patients with a history of failure to IFN-free DAA therapy or with double RASs in HCV-NS5A remained difficult to treat with this regimen.
Internal Medicine | 2018
Haruki Uojima; Shuko Murakami; Seigo Nakatani; Hisashi Hidaka; Atsuko Takeuchi; Yoshiaki Tanaka; Tomoyoshi Inoue; Keiko Yamane; Kousuke Kubota; Takahide Nakazawa; Akitaka Shibuya; Yasuhito Tanaka; Wasaburo Koizumi
There have been few studies on relapse after a sustained virological response in hepatitis C virus (HCV) patients treated with interferon-free regimens. Thus, the risk of late relapse in patients treated with interferon-free therapy remains unclear. A 67-year-old woman with HCV genotype 1b and liver cirrhosis received oral daclatasvir and asunaprevir. Combination therapy was stopped after 4 weeks because of an episode of encephalopathy. Nonetheless, an HCV polymerase chain reaction at 24 weeks posttreatment was negative. However, HCV ribonucleic acid was detectable at approximately 62 weeks posttreatment. Very late HCV relapses may occur in patients with liver cirrhosis who receive an interferon-free regimen when the treatment period is insufficient.
Hepatology Research | 2018
Kousuke Kubota; Hisashi Hidaka; Takahide Nakazawa; Yusuke Okuwaki; Keiko Yamane; Tomoyoshi Inoue; Haruki Uojima; Juichi Takada; Yoshiaki Tanaka; Akitaka Shibuya; Kaoru Fujii; Reiko Woodhams; Keiji Matsunaga; Shigehiro Kokubu; Wasaburo Koizumi
Transcatheter arterial chemoembolization (TACE) has been recognized as a treatment option for patients with intermediate hepatocellular carcinoma (HCC). This randomized, controlled study compared the local control efficacy of TACE with miriplatin (platinum monohydrate) or with epirubicin.
World Journal of Gastroenterology | 2017
Haruki Uojima; Hisashi Hidaka; Tsuyoshi Nakayama; Ji Hyun Sung; Chikamasa Ichita; Shinnosuke Tokoro; Sakue Masuda; Akiko Sasaki; Kazuya Koizumi; Hideto Egashira; Makoto Kako
AIM To assess the effects of a combination therapy with natriuretic and aquaretic drugs in cirrhotic ascites patients. METHODS A two-center, randomized, open-label, prospective study was conducted. Japanese patients who met the criteria were randomized to trial group and the combination diuretic group (received 7.5 mg of tolvaptan) or the conventional diuretic group (received 40 mg of furosemide) for 7 d in addition to the natriuretic drug which was used prior to enrolment in this study. The primary endpoint was the change in body weight from the baseline. Vital signs, fluid intake, and laboratory and urinary data were assessed to determine the pharmacological effects after administration of aquaretic and natriuretic drugs. RESULTS A total of 56 patients were randomized to receive either tolvaptan (n = 28) or furosemide (n = 28). In the combination and conventional diuretic groups, the average decrease in body weight from the baseline was 3.21 ± 3.17 kg (P < 0.0001) and 1.75 ± 2.36 kg (P = 0.0006), respectively, when measured on the final dosing day. Following 1 wk of treatment, a significantly greater reduction in body weight was observed in the combination diuretic group compared to that in the conventional diuretic group (P = 0.0412). CONCLUSION Compared to a conventional diuretic therapy with only a natriuretic drug, a combination diuretic therapy with natriuretic and aquaretic drugs is more effective for patients with cirrhotic ascites.
World Journal of Gastroenterology | 2016
Akiko Sasaki; Takeshi Nakajima; Hideto Egashira; Kotaro Takeda; Shinnosuke Tokoro; Chikamasa Ichita; Sakue Masuda; Haruki Uojima; Kazuya Koizumi; Takeshi Kinbara; Taku Sakamoto; Yutaka Saito; Makoto Kako
Condyloma acuminatum (CA) is a common sexually transmitted disease caused by human papilloma virus infection. Not all individuals develop persistent, progressive disease, but careful follow up is required with moderate-to-severe dysplasia to prevent progression to malignancy. Standard therapies include surgical treatments (trans-anal resection and trans-anal endoscopic microsurgery) and immunotherapeutic and topical methods (topical imiquimod); however, local recurrence remains a considerable problem. Here, we report a case with superficial CA of the anal canal, treated with endoscopic submucosal dissection (ESD). A 28-year-old man presented with a chief complaint of hematochezia. Digital exam did not detect a tumor. Screening colonoscopy revealed 10-mm long, whitish condyles extending from the anal canal to the lower rectum. The lesion covered almost the whole circumference, and only a small amount of normal mucosa remained. Magnifying endoscopy with narrow band imaging showed brownish hairpin-shaped, coiled capillaries. Although histopathological diagnosis by biopsy revealed CA, accurate histological differentiation between CA, papilloma, and squamous cell carcinoma can be difficult with a small specimen. Therefore, we performed diagnostic ESD, which provides a complete specimen for precise histopathological evaluation. The pathological diagnosis was CA, with moderate dysplasia (anal intraepithelial neoplasia 2). There was no recurrence at 16 mo after the initial ESD. Compared to surgical treatment, endoscopic diagnosis and resection could be performed simultaneously and the tumor margin observed clearly with a magnifying chromocolonoscopy, resulting in less recurrence. These findings suggest that endoscopic resection may be an alternative method for CA that prevents recurrence.
Journal of Gastroenterology and Hepatology | 2018
Masanori Atsukawa; Akihito Tsubota; Hidenori Toyoda; Koichi Takaguchi; Chisa Kondo; Tomomi Okubo; Atsushi Hiraoka; Kojiro Michitaka; Shinichi Fujioka; Haruki Uojima; Tsunamasa Watanabe; Hiroki Ikeda; Toru Asano; Hiroshi Abe; Keizo Kato; Kunihiko Tsuji; Chikara Ogawa; Noritomo Shimada; Etsuko Iio; Shigeru Mikami; Yasuhito Tanaka; Takashi Kumada; Katsuhiko Iwakiri
This study aimed to evaluate the efficacy and safety of elbasvir/grazoprevir in genotype 1b chronic hepatitis C Japanese patients with chronic kidney disease (CKD), including those undergoing hemodialysis.
Journal of Gastroenterology and Hepatology | 2018
Haruki Uojima; Hisashi Hidaka; Yoshiaki Tanaka; Tomoyoshi Inoue; Mie Onoue; Naohisa Wada; Kousuke Kubota; Takahide Nakazawa; Akitaka Shibuya; Tomoaki Fujikawa; Tsuyoshi Nakayama; Hiroki Yamanoue; Ji Hyun Sung; Makoto Kako; Wasaburo Koizumi
An assay for Wisteria floribunda agglutinin‐positive human Mac‐2 binding protein (WFA+‐M2BP) has been reported as a useful non‐invasive marker for the evaluation of the staging of fibrosis in several chronic liver diseases. However, available data on the effect of WFA+‐M2BP level in decompensated cirrhosis patients were limited. It is important that these investigations can validate the diagnostic utility of WFA+‐M2BP in the full range of patients with liver cirrhosis.
Internal Medicine | 2017
Ji Hyun Sung; Haruki Uojima; Joel Branch; Sho Miyazono; Izumi Kitagawa; Makoto Kako; Shuzo Kobayashi
An 83-year-old man was admitted with a chief complaint of exacerbation of dyspnea. His blood oxygen saturation was 90% in the recumbent position despite oxygen therapy, and it dropped to less than 80% when the patient attempted to sit upright. A computed tomography scan revealed a giant hepatic cyst compressing the right atrium and the inferior vena cava. After percutaneous drainage, the oxygen saturation improved and did not change with alteration of the patients positions from recumbent to sitting or standing. This case report describes a patient with the platypnea-orthodeoxia syndrome due to a giant hepatic cyst successfully managed by percutaneous drainage.
Hepatology Research | 2017
Yoshiaki Tanaka; Takahide Nakazawa; Tomoyoshi Inoue; Keiko Yamane; Kousuke Kubota; Haruki Uojima; Juichi Takada; Yusuke Okuwaki; Hisashi Hidaka; Akitaka Shibuya; Shigehiro Kokubu; Keiji Matsunaga; Wasaburo Koizumi
To examine whether superparamagnetic iron oxide (SPIO)‐enhanced magnetic resonance imaging (MRI) can be used to assess the malignant potential of hepatic hypovascular nodules showing hypointensity during the hepatobiliary phase (HBP) on gadoxetic acid (Gd–EOB–DTPA)‐enhanced MRI.